Global Plasma Therapy Market is valued approximately USD 261.08 million in 2021 and is anticipated to grow with a healthy growth rate of more than 14.0% over the forecast period 2022-2028.
Plasma is one of the components that are present in the blood, which carries essential nutrients, hormones, and proteins to the body parts that need it. The primary objective of plasma therapy is to transfer the immunity of a healthy individual to another patient. The plasma generally encompasses a large number of antibodies that aid in curing various diseases. The growing incidences of sports injuries, rising number of patients suffering from androgenic alopecia, arthritis, and orthopedic disorders, and increasing adoption of platelet-rich plasma in various therapeutic applications are the chief factors that accelerate the market growth across the globe. For instance, according to the Centers for Disease Control and Prevention, in 2015, nearly 54 million adult population were diagnosed with arthritis in the United States. Also, the amount is projected to reach approximately 72 million by the end of 2030. Consequentially, the rising prevalence of arthritis is likely to fuel the demand for plasma therapy, which, in turn, accelerates market growth. However, the lack of reimbursement policies and restricted use of
platelet-rich plasma (PRP) for patients suffering from diabetes and kidney ailments impedes the growth of the market over the forecast period of 2022-2028. Also, the development of the emerging economies and rising expenditure in the healthcare sector are anticipated to act as a catalyzing factor for the market demand during the forecast period.
The key regions considered for the global Plasma Therapy market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing investment for R&D activities and the presence of leading market players in the region. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the growing presence of the geriatric population as well as rising incidences of orthopedic disorder, would create lucrative growth prospects for the Plasma Therapy market across the Asia-Pacific region.
Major market players included in this report are:
BioLife Plasma Services
Cambryn Biologics LLC
Biotest AG
CSL Ltd.
Grifols International S.A.
Kedrion S.p.A.
LFB S.A.
Bio Products Laboratory Ltd.
China Biologic Products, Inc.
Octapharma AG
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Pure PRP
Leucocyte-rich PRP
Pure Platelet-rich Fibrin (PRF)
Leukocyte-rich Fibrin (L-PRF)
By Source:
Autologous
Allogenic
By Application:
Orthopedics
Dermatology
Dental
Cardiac Muscle Injury
Nerve Injury
Others
By End User:
Hospitals & Clinics
Research Institutions
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019, 2020
Base year - 2021
Forecast period - 2022 to 2028
Target Audience of the Global Plasma Therapy Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
